Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$31.39 -2.5%	$32.54	$20.20 ▼ $43.11	$1.59B	1.56	606,890 shs	479,144 shs
CMD Cantel Medical	$80.37	$82.48	$39.40 ▼ $89.76	$3.58B	1.55	626,604 shs	N/A
HAE Haemonetics	$76.26 -0.1%	$68.51	$55.30 ▼ $94.99	$3.67B	0.39	671,508 shs	489,218 shs
MMSI Merit Medical Systems	$93.51 -0.5%	$94.80	$82.62 ▼ $111.45	$5.55B	0.65	536,889 shs	336,902 shs
NUVA NuVasive	$39.75	$39.64	$35.17 ▼ $49.53	$2.08B	1.07	1.16 million shs	N/A

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	-1.74%	-1.65%	-6.77%	-5.65%	+43.11%
CMD Cantel Medical	0.00%	0.00%	0.00%	0.00%	0.00%
HAE Haemonetics	+2.16%	+4.28%	+12.87%	+19.19%	-7.72%
MMSI Merit Medical Systems	+0.53%	+0.77%	-1.13%	-12.20%	+9.74%
NUVA NuVasive	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRC AtriCure	3.5524 of 5 stars	3.5	5.0	0.0	0.0	2.5	2.5	0.6
CMD Cantel Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HAE Haemonetics	4.8569 of 5 stars	4.5	2.0	0.0	4.3	2.1	1.7	2.5
MMSI Merit Medical Systems	4.3739 of 5 stars	3.4	2.0	0.0	3.8	2.6	2.5	1.3
NUVA NuVasive	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRC AtriCure	3.00	Buy	$50.67	61.41% Upside
CMD Cantel Medical	0.00	N/A	N/A	N/A
HAE Haemonetics	2.91	Moderate Buy	$96.80	26.93% Upside
MMSI Merit Medical Systems	2.89	Moderate Buy	$109.11	16.68% Upside
NUVA NuVasive	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MMSI, HAE, NUVA, CMD, and ATRC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	HAE Haemonetics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/25/2025	HAE Haemonetics	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/23/2025	MMSI Merit Medical Systems	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$106.00 ➝ $110.00
5/21/2025	MMSI Merit Medical Systems	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$108.00 ➝ $112.00
5/21/2025	MMSI Merit Medical Systems	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$106.00 ➝ $108.00
5/20/2025	HAE Haemonetics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$100.00 ➝ $100.00
5/15/2025	MMSI Merit Medical Systems	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $108.00
5/9/2025	HAE Haemonetics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$115.00 ➝ $105.00
5/8/2025	HAE Haemonetics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$104.00 ➝ $84.00
4/30/2025	ATRC AtriCure	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$60.00 ➝ $60.00
4/30/2025	ATRC AtriCure	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $58.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRC AtriCure	$465.31M	3.34	N/A	N/A	$9.46 per share	3.32
CMD Cantel Medical	$1.02B	3.52	$3.38 per share	23.78	$17.31 per share	4.64
HAE Haemonetics	$1.36B	2.69	$7.20 per share	10.59	$16.34 per share	4.67
MMSI Merit Medical Systems	$1.36B	4.07	$5.58 per share	16.76	$23.67 per share	3.95
NUVA NuVasive	$1.23B	1.70	$4.96 per share	8.01	$17.02 per share	2.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRC AtriCure	-$44.70M	-$0.81	N/A	N/A	N/A	-7.95%	-5.68%	-4.34%	7/29/2025 (Estimated)
CMD Cantel Medical	$13.71M	$1.65	69.28	28.91	1.63	4.72%	12.13%	4.45%	N/A
HAE Haemonetics	$167.68M	$3.31	23.04	15.13	1.24	12.32%	26.37%	9.22%	8/14/2025 (Estimated)
MMSI Merit Medical Systems	$120.36M	$2.04	45.84	24.94	3.10	8.81%	15.52%	8.72%	7/30/2025 (Estimated)
NUVA NuVasive	$40.41M	$0.50	79.50	15.35	N/A	2.32%	12.17%	4.88%	N/A

Latest MMSI, HAE, NUVA, CMD, and ATRC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	ATRC AtriCure	-$0.15	N/A	N/A	N/A	$130.17 million	N/A
5/8/2025	Q4 2025	HAE Haemonetics	$1.22	$1.24	+$0.02	$1.17	$329.38 million	$330.60 million
4/29/2025	Q1 2025	ATRC AtriCure	-$0.25	-$0.14	+$0.11	-$0.14	$122.92 million	$123.62 million
4/24/2025	Q1 2025	MMSI Merit Medical Systems	$0.75	$0.86	+$0.11	$0.49	$352.57 million	$355.35 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
CMD Cantel Medical	$0.21	0.26%	N/A	12.73%	N/A
HAE Haemonetics	N/A	N/A	N/A	N/A	N/A
MMSI Merit Medical Systems	N/A	N/A	N/A	N/A	N/A
NUVA NuVasive	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRC AtriCure	0.16	4.11	2.88
CMD Cantel Medical	1.16	2.72	2.00
HAE Haemonetics	1.12	1.62	0.99
MMSI Merit Medical Systems	0.51	4.87	3.26
NUVA NuVasive	0.50	1.25	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRC AtriCure	99.11%
CMD Cantel Medical	84.13%
HAE Haemonetics	99.67%
MMSI Merit Medical Systems	99.66%
NUVA NuVasive	N/A

Insider Ownership

Company	Insider Ownership
ATRC AtriCure	3.50%
CMD Cantel Medical	10.70%
HAE Haemonetics	1.84%
MMSI Merit Medical Systems	3.20%
NUVA NuVasive	0.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRC AtriCure	1,300	49.51 million	47.77 million	Optionable
CMD Cantel Medical	3,669	44.51 million	N/A	Optionable
HAE Haemonetics	3,023	48.04 million	47.16 million	Optionable
MMSI Merit Medical Systems	7,400	59.10 million	57.21 million	Optionable
NUVA NuVasive	3,000	52.45 million	52.17 million	Optionable

MMSI, HAE, NUVA, CMD, and ATRC Headlines

Recent News About These Companies

The 5 Most Interesting Analyst Questions From Globus Medical’s Q1 Earnings Call

July 1 at 10:03 AM | msn.com

Analysts downgrade Globus Medical on fears of ‘foundational cracks’

May 27, 2025 | massdevice.com

BTIG Downgrades Globus Medical (GMED) to Neutral on Spine Business Concerns

May 27, 2025 | msn.com

Globus Medical Q1 sales dip slightly: 5 notes

May 10, 2025 | beckersspine.comB

Verdict Against NuVasive in Patent Dispute

May 9, 2025 | ryortho.comR

5 patent battles to know

May 2, 2025 | beckersasc.comB

NuVasive infringed surgeon’s spine patents, jury says

April 24, 2025 | beckersspine.comB

Artificial Tendons and Ligaments Market Expected to Hit USD 2.7 Billion by 2035 with a Remarkable 10.46% CAGR

April 23, 2025 | biznes.newseria.plB

NuVasive Infringes Surgeon’s Spinal-Screws Patents, Jury Says

April 22, 2025 | news.bloomberglaw.comN

Spine company names Keith Valentine CEO

April 11, 2025 | beckersspine.comB

The Perils of Procedural Misadventure and Unclear Claim Drafting in Patent Litigation

March 26, 2025 | jdsupra.com

Global Medical Handily Beats 2024 Sales Estimates

March 14, 2025 | ryortho.comR

Globus Medical targets $2.8B-$2.9B revenue in 2025 with Nevro acquisition integration

February 21, 2025 | msn.com

Globus Medical Q4, 2024 sales rise

February 20, 2025 | beckersspine.comB

Globus Medical: Some Caution After Its Deal For Nevro

February 16, 2025 | seekingalpha.com

Florida Sales Rep Ordered to Pay $19 million

February 10, 2025 | ryortho.comR

Globus acquisition of Nevro complicates story, says Stifel

February 6, 2025 | markets.businessinsider.com

BTIG maintains $91 target on Globus Medical stock post-acquisition

February 6, 2025 | msn.com

SMAIO Provides Update on Its Partnership With NuVasive and Confirms Its Strategic Focus on the U.S. Market

January 27, 2025 | uk.finance.yahoo.com

NuVasive, SMAIO end orthopedic partnership

January 27, 2025 | beckersspine.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

MMSI, HAE, NUVA, CMD, and ATRC Company Descriptions

AtriCure NASDAQ:ATRC

$31.39 -0.81 (-2.52%)

Closing price 04:00 PM Eastern

Extended Trading

$31.35 -0.04 (-0.12%)

As of 06:48 PM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Cantel Medical NYSE:CMD

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.

Haemonetics NYSE:HAE

$76.26 -0.06 (-0.08%)

Closing price 03:59 PM Eastern

Extended Trading

$75.60 -0.67 (-0.87%)

As of 04:42 PM Eastern

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Merit Medical Systems NASDAQ:MMSI

$93.51 -0.47 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$93.51 +0.00 (+0.00%)

As of 06:48 PM Eastern

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions. It also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, manifold kits, and trays and packs; coating services for medical tubes and wires; and sensor components for microelectromechanical systems. In addition, the company provides pulmonary products that consist of laser-cut tracheobronchial stents, over-the-wire and direct visualization delivery systems, and dilation balloons to endoscopically dilate structures; gastroenterology products, such as covered esophageal stents, syringe and gauges, and balloon dilators; and kits and accessories for endoscopy and bronchoscopy procedures. It sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.

NuVasive NASDAQ:NUVA

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time